Allergan expands neurological portfolio with $125m Chase Pharmaceuticals buy

Allergan (NYSE:AGN) said today that it acquired Chase Pharmaceuticals for an upfront payment of $125 million, expanding the Dublin-based company’s neurological portfolio.

Washington, D.C.-based Chase is developing a combination therapy of an acetylcholinesterase inhibitor and a cholinergic blocker in the hopes of improving cognition in patients with Alzheimer’s disease. The acetylcholinesterase inhibitors available on the market are limited to small doses because of the side effects, which include diarrhea, nausea and vomiting.  Chase touted results from phase II clinical trials, where 88% of patients reached the maximum allowable dose without experiencing dose-limiting adverse events.

Get the full story at our sister site, Drug Delivery Business News.

The post Allergan expands neurological portfolio with $125m Chase Pharmaceuticals buy appeared first on MassDevice.

from MassDevice http://ift.tt/2fr7ICg